ZEBETA Drug Patent Profile

When do Zebeta patents expire, and what generic alternatives are available?

Zebeta is a drug marketed by Teva Womens and is included in one NDA.

The generic ingredient in ZEBETA is bisoprolol fumarate. There are twelve drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the bisoprolol fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zebeta

A generic version of ZEBETA was approved as bisoprolol fumarate by RUBICON on November 16^th, 2000.

Summary for ZEBETA

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	212
Clinical Trials:	3
Patent Applications:	4,567
DailyMed Link:	ZEBETA at DailyMed

Recent Clinical Trials for ZEBETA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Heart Center BH Tuzla	Early Phase 1
IPCA Laboratories Ltd.	Phase 1

See all ZEBETA clinical trials

US Patents and Regulatory Information for ZEBETA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Womens	ZEBETA	bisoprolol fumarate	TABLET;ORAL	019982-002	Jul 31, 1992		DISCN	Yes	No
Teva Womens	ZEBETA	bisoprolol fumarate	TABLET;ORAL	019982-001	Jul 31, 1992		DISCN	Yes	No

Expired US Patents for ZEBETA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Womens	ZEBETA	bisoprolol fumarate	TABLET;ORAL	019982-002	Jul 31, 1992	4,258,062*PED
Teva Womens	ZEBETA	bisoprolol fumarate	TABLET;ORAL	019982-001	Jul 31, 1992	4,258,062*PED

International Patents for ZEBETA

See the table below for patents covering ZEBETA around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	177868	PROCESS FOR PREPARING PHENOXY-AMINO-PROPANOLS
Hong Kong	39483	PHENOXY-AMINO-PROPANOLS AND PROCESSES FOR THEIR PREPARATION
Australia	520307
Netherlands	185665
United Kingdom	1532380

ZEBETA Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for ZEBETA (Bisoprolol)

Introduction to ZEBETA (Bisoprolol)

ZEBETA, also known by its generic name bisoprolol, is a cardio-selective beta blocker used primarily to treat hypertension, angina, and certain types of heart failure. It belongs to the class of beta-1 selective blockers, which target the heart specifically, reducing the workload on the heart and lowering blood pressure.

Market Size and Growth

The global beta blockers market, which includes ZEBETA, is experiencing steady growth driven by several key factors.

• Increasing Prevalence of Cardiovascular Diseases: The rise in cardiovascular diseases such as hypertension, heart failure, and angina is a significant driver. As the global population ages, the incidence of these diseases increases, leading to higher demand for beta blockers like ZEBETA[1][4].
• Geriatric Population Growth: The aging population is another crucial factor. Older individuals are more likely to suffer from cardiovascular conditions, thereby increasing the demand for beta blockers[1][4].

Market Segmentation

The beta blockers market, including ZEBETA, can be segmented in several ways:

• By Type: Beta-1 selective blockers, such as bisoprolol, and non-selective blockers. Bisoprolol, the active ingredient in ZEBETA, falls under the beta-1 selective category[1][4].
• By Application: Cardiac diseases, hypertension, angina, and heart failure. ZEBETA is predominantly used for treating hypertension and heart failure[1][4].
• By Distribution Channel: Hospital pharmacies, retail pharmacies, and online pharmacies. ZEBETA is widely available through these channels[1][4].

Regional Analysis

• North America: This region is expected to account for the largest share of the beta blockers market, including ZEBETA, due to the high prevalence of heart-related diseases and a well-developed healthcare system[1][4].
• Asia Pacific: This region is anticipated to witness the fastest growth during the forecast period, driven by an aging population, increasing awareness of beta blockers, and the need for better healthcare infrastructure[1][4].

Financial Trajectory

The financial performance of the beta blockers market, including ZEBETA, is influenced by several factors:

• Market Size: The global beta blockers market was valued at approximately $9.1 billion in 2022 and is projected to reach more than $14.4 billion by 2031, growing at a CAGR of 5.2% from 2023 to 2031[1].
• Revenue Forecast: The cardio-selective beta blockers market, which includes ZEBETA, is expected to surpass $10.1 billion by 2031, expanding at a CAGR of 5.7% during the forecast period[4].

Key Players and Competition

The beta blockers market is fragmented with several key players:

• Major Players: Companies such as Mylan N.V., Novartis AG, Pfizer Inc., Abbott, Teva Pharmaceutical Industries Ltd., and Sun Pharmaceutical Industries Ltd. are significant players in the market. These companies are investing heavily in research and development to introduce new formulations and drug delivery systems[1][4].

Research and Development

Pharmaceutical companies are focusing on developing new and improved beta blockers:

• New Formulations: There is a surge in the development of new formulations and drug delivery technologies to enhance the efficacy, safety, and tolerability of beta blockers like ZEBETA[1][4].
• Combination Therapies: The launch of combination therapies and novel drug delivery systems is also driving market expansion[1].

Challenges and Restraints

Despite the growth, the market faces several challenges:

• Alternative Drugs: The availability of alternative drugs such as calcium channel blockers and ACE inhibitors can hamper the growth of the beta blockers market[4].
• Patent Expiration: The patent expiration of several blockbuster drugs, including some beta blockers, can also restrain market development[4].

Market Attractiveness Analysis

The attractiveness of the beta blockers market, including ZEBETA, can be analyzed based on several factors:

• By Type: Beta-1 selective blockers like bisoprolol are highly attractive due to their targeted action on the heart[1][4].
• By Application: The cardiac diseases segment, which includes heart failure and hypertension, holds a significant share and is highly attractive[1][4].
• By Distribution Channel: Hospital pharmacies and retail pharmacies remain the most attractive channels due to their widespread presence and accessibility[1][4].

Regulatory Approvals and Innovations

Recent regulatory approvals and innovations are crucial for the market:

• FDA Approvals: For instance, approvals for extended indications of drugs like Entresto by Novartis have broadened the treatment spectrum for heart failure, which indirectly benefits the beta blockers market by highlighting the importance of cardiovascular treatments[3].

Asia Pacific Market Growth

The Asia Pacific region is expected to register substantial growth:

• Innovative Therapies: The introduction of innovative therapies to manage heart failure and the approval of first-in-class medications are driving revenue growth in this region[3].

Key Takeaways

• Growing Demand: The demand for beta blockers like ZEBETA is increasing due to the rising prevalence of cardiovascular diseases and the aging population.
• Regional Growth: North America and Asia Pacific are key regions driving the market growth.
• Research and Development: Continuous investment in R&D is crucial for introducing new and improved formulations.
• Challenges: The market faces challenges from alternative drugs and patent expirations.

FAQs

Q: What is the primary use of ZEBETA (bisoprolol)? A: ZEBETA (bisoprolol) is primarily used to treat hypertension, angina, and certain types of heart failure.

Q: What drives the growth of the beta blockers market? A: The growth is driven by the increasing prevalence of cardiovascular diseases and the rise in the geriatric population.

Q: Which region is expected to account for the largest share of the beta blockers market? A: North America is expected to account for the largest share of the beta blockers market.

Q: What are the challenges faced by the beta blockers market? A: The market faces challenges from alternative drugs like calcium channel blockers and ACE inhibitors, as well as patent expirations.

Q: How is the Asia Pacific region contributing to the growth of the beta blockers market? A: The Asia Pacific region is contributing through the introduction of innovative therapies and the approval of first-in-class medications for managing heart failure.

Sources

1. Transparency Market Research: Beta Blockers Market Size, Share, Growth, Industry Report - 2031
2. Jazz Pharmaceuticals: Full Year and Fourth Quarter 2021 Financial Results
3. Emergen Research: Heart Failure Drugs Market Size, Trend, Demand Analysis Till 2032
4. Transparency Market Research: Cardio-selective Beta Blockers Market Size, Trends, Analysis to 2031